Department of Medicine and Clinical Science, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Hepatol Res. 2006 Apr;34(4):222-7. doi: 10.1016/j.hepres.2006.01.004. Epub 2006 Mar 3.
Interferon (IFN)-beta is known to be involved in the regulation of bone homeostasis. As IFN-alpha and -beta share the same receptor complex and signaling pathway, we speculated that treatment with IFN-alpha for chronic hepatitis C (CHC) may provide a beneficial effect on bone loss.
Urinary deoxypyridinoline (uDPD) of 41 patients with CHC who had been receiving IFN-alpha for 24 weeks was examined during the period of observation. Among them, eight patients showed a bone mineral density (BMD) of less than 0.850g/cm(2) before IFN therapy and they were examined a BMD again after completion of IFN administration. Relationships between the percentage difference of uDPD after discontinuation of IFN and various factors related to CHC were also examined.
A mean uDPD of 7.1+/-3.4nM/mM creatinine before IFN therapy decreased to 4.5+/-2.4 in the 4th week and 4.2+/-2.7 in the 24th week of IFN therapy, respectively (p<0.0001). The reduction in uDPD was more prominent in cases with a lower viral load (p=0.0266). The BMD of the eight patients, which was less than 0.850g/cm(2) before IFN therapy, showed significant increase after the end of therapy (p=0.0172).
IFN-alpha can improve bone resorption in CHC patients, especially in those with a lower viral load, and increased BMD. These effects are thought to be a result of direct action of IFN on bone homeostasis.
干扰素（IFN）-β 已知参与骨稳态的调节。由于 IFN-α 和 -β 共享相同的受体复合物和信号通路，我们推测用 IFN-α 治疗慢性丙型肝炎（CHC）可能对骨质流失有有益作用。
在观察期间，检查了接受 IFN-α 治疗 24 周的 41 例 CHC 患者的尿脱氧吡啶啉（uDPD）。其中，8 例患者在 IFN 治疗前 BMD 低于 0.850g/cm(2)，在 IFN 给药结束后再次检查 BMD。还检查了 uDPD 在 IFN 停药后百分比变化与与 CHC 相关的各种因素之间的关系。
IFN 治疗前 uDPD 的平均值为 7.1+/-3.4nM/mM 肌酐，分别在 IFN 治疗的第 4 周和第 24 周下降至 4.5+/-2.4 和 4.2+/-2.7（p<0.0001）。病毒载量较低的患者 uDPD 减少更为明显（p=0.0266）。在 IFN 治疗前 BMD 低于 0.850g/cm(2)的 8 例患者，在治疗结束后 BMD 显示出显著增加（p=0.0172）。
IFN-α 可改善 CHC 患者的骨吸收，特别是病毒载量较低的患者，BMD 增加。这些作用被认为是 IFN 对骨稳态的直接作用的结果。
